Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sky Century InvestmentSKYI +15.82%29 PS Ratio is 5.41 as of Jul. 23, 2026, which is 85% below its 10-year median of 36.67. GuruFocus rates SKYI with a GF Score™ of 29/100. The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Sky Century Investment ranks worse than 72.48% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sky Century Investment's share price is $0.265.
Sky Century Investment's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was $0.05. Hence, Sky Century Investment's PS Ratio for today is 5.41.
The historical rank and industry rank for Sky Century Investment's PS Ratio or its related term are showing as below:
SKYI'
s PS Ratio Range Over the Past 10 Years
Min: 2.04 Med: 36.67 Max: 98
Current: 5.43
During the past 6 years, Sky Century Investment's highest PS Ratio was 98.00. The lowest was 2.04. And the median was 36.67.
SKYI's PS Ratio is ranked worse than 72.48% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.295
vs SKYI: 5.43
Sky Century Investment (OTCPK:SKYI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sky Century Investment's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sky Century Investment PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sky Century Investment's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sky Century Investment's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sky Century Investment's Share Price of today is $0.265. Sky Century Investment's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sky Century Investment (SKYI) has a PS Ratio of 5.41 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sky Century Investment and its competitors. This is 85% below median its historical median of 36.67. Over the past decade, Sky Century Investment's PS Ratio has ranged from 2.04 to 98.00. According to the industry distribution chart, Sky Century Investment ranks #690 out of 952 companies in the Drug Manufacturers industry, placing it in the top 72.5%.
Is Sky Century Investment's PS Ratio too high?
Sky Century Investment's current PS Ratio of 5.41 is 85% below median its 10-year median of 36.67. Over the past 10 years, this metric has ranged from a low of 2.04 to a high of 98.00. The Drug Manufacturers industry median PS Ratio is 2.30. Sky Century Investment's value of 5.41 is 135.7% above this industry median. Based on the distribution chart, Sky Century Investment ranks #690 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sky Century Investment has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Sky Century Investment's PS Ratio compare to IMCC and PLSH?
According to the Drug Manufacturers industry distribution chart, Sky Century Investment ranks #690 out of 952 companies for PS Ratio. This places Sky Century Investment in the lower half of its industry. The industry median PS Ratio is 2.30. Sky Century Investment's value of 5.41 is 135.7% above this benchmark. Historically, Sky Century Investment's own PS Ratio has ranged from 2.04 to 98.00 over the past decade. While the company's 10-year median is 36.67 vs. the industry median of 2.30, Sky Century Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sky Century Investment's current PS Ratio of 5.41 is 135.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sky Century Investment and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sky Century Investment's current PS Ratio is 5.41, which is 85% below median its own 10-year median of 36.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sky Century Investment stock overvalued right now?
Sky Century Investment (SKYI) has a current PS Ratio of 5.41. The current PS Ratio is 5.41, which is 85% below median its 10-year median of 36.67 and 135.7% above the Drug Manufacturers industry median of 2.30. Sky Century Investment's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sky Century Investment (SKYI), the current PS Ratio is 5.41 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sky Century Investment Inc operates four primary business lines, with profits generated from IT Services, including Technical Support and Server Leasing, and from the sale of RSS feeds and Podcasts. The IT Services segment provides ongoing technical support, maintenance, system upgrades, and high-performance server leasing, supporting growing demand for cloud solutions, data management, and network infrastructure. The Company also owns the Cannabis News application, a mobile platform that aggregates cannabis-related news from diverse sources and delivers real-time updates, though it is not commercially viable and has not generated revenue to date. The Company operates in competitive markets across IT services, marketing services, RSS feed services, and the cannabis industry.
29GF Score
Get the complete analysis for SKYI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SKYI has been successfully added to your 
